About AOD-9604
A C-terminal fragment of human growth hormone studied for fat metabolism activity without the growth-promoting or glucose-altering effects of full HGH.
Research dose ranges
- Dose: 300–500 mcg per administration
- Frequency: 1× per day
- Route: subcutaneous
- Half-life: ~0.75 hours
- Cycle: 12 weeks on / 4 off
Research protocols typically use 300–500 mcg subcutaneously once daily in a fasted state, often in the morning. Oral formulations were also studied in clinical trials at higher mg doses.
Storage
Lyophilized vials stable at 2–8°C. Refrigerate reconstituted solution and use within 30 days.